2m 2m 2m 2m 2m 2m 2m
FOGHORN THERAP (FHTX)
NASDAQ
$3.70+$0.06 (+1.62%)
Price as of Jun 03, 2026 7:54 PM EDT- $251.3MMarket Cap
- -16.74%1-Year Change
- BiotechnologyIndustry
FOGHORN THERAP (FHTX)
$3.70+$0.06 (+1.62%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 30.9M +36.75% | 22.6M -33.83% | 34.2M +77.63% | 19.2M +1,357.77% | |
Cost of Revenue | N/A N/A | 17.4M N/A | N/A N/A | N/A N/A | |
Gross Profit | 30.9M +496.47% | 5.2M -84.83% | 34.2M +77.63% | 19.2M +1,357.77% | |
Sales and Marketing Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Research and Development Expense | -85.5M -9.59% | -94.5M -13.82% | -109.7M +3.85% | -105.6M +31.49% | |
Depreciation and Amortization Expense | 3.3M +6.79% | 3.1M -9.59% | 3.5M +3.91% | 3.3M +2.91% | |
Total Operating Expenses | 117.3M -6.38% | 125.3M -11.81% | 142.1M +4.18% | 136.4M +33.62% | |
Operating Profit | -86.4M -15.87% | -102.7M -4.84% | -107.9M -7.88% | -117.1M +16.28% | |
Interest Income | 8.7M -26.51% | 11.9M +9.43% | 10.9M +91.63% | 5.7M N/A | |
Interest Expense | N/A N/A | N/A N/A | N/A N/A | 0 +100.00% | |
Interest Income and Expense and Net | 8.7M -26.51% | 11.9M +9.43% | 10.9M +91.63% | 5.7M +397.74% | |
Total Nonoperating Income and Expense | 12.1M -24.63% | 16.1M +17.20% | 13.7M +66.03% | 8.3M +1,508.70% | |
Income before Taxes | -86.4M -0.27% | -86.6M -8.05% | -94.2M -19.58% | -117.1M +16.28% | |
Income Taxes | 0 N/A | 0 -100.00% | 4.2M N/A | N/A N/A | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | -74.3M -14.24% | -86.6M -11.99% | -98.4M -9.60% | -108.9M +7.46% | |
Net Income from Continuing Operations Applicable to Common | -74.3M -14.24% | -86.6M -8.05% | -94.2M -13.48% | -108.9M +7.46% | |
Basic EPS and Net Income | -1.18 -25.32% | -1.58 -32.48% | -2.34 -10.69% | -2.62 -4.03% | |
Diluted EPS and Net Income | -1.18 -25.32% | -1.58 -32.48% | -2.34 -10.69% | -2.62 -4.03% | |
Basic Weighted Average Shares | 63.0M +14.72% | 54.9M +30.79% | 42.0M +0.92% | 41.6M +11.89% | |
Diluted Weighted Average Shares | 63.0M +14.72% | 54.9M +30.79% | 42.0M +0.92% | 41.6M +11.89% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 80.9M +45.84% | 55.5M -30.97% | 80.3M +53.86% | 52.2M -48.37% | |
Short-Term Investments | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash and Cash Equivalents and Short-Term Investments | 80.9M +45.84% | 55.5M -30.97% | 80.3M +53.86% | 52.2M -48.37% | |
Total Current Assets | 163.2M -34.60% | 249.6M +3.92% | 240.2M -31.65% | 351.4M -23.54% | |
Accumulated Depreciation | 7.0M -53.56% | 15.1M +25.52% | 12.0M +39.55% | 8.6M +61.56% | |
Property and Plant and Equipment and Net | 1.9M -80.78% | 10.0M -23.09% | 13.0M -15.38% | 15.3M -12.82% | |
Total Long-Term Assets | 4,000 -94.12% | 68,000 -93.90% | 1.1M -53.13% | 2.4M -0.87% | |
Total Assets | 198.1M -30.24% | 284.0M -0.68% | 285.9M -29.38% | 404.9M -22.10% | |
Income Taxes Payable | N/A N/A | 0 -100.00% | 674,000 N/A | N/A N/A | |
Total Short-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Current Liabilities | 59.7M -10.82% | 67.0M +14.64% | 58.4M +5.85% | 55.2M +13.38% | |
Total Long-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Long-Term Liabilities | 556,000 -99.79% | 262.5M N/A | 0 -100.00% | 29,000 -79.72% | |
Total Liabilities | 306.6M -6.95% | 329.5M -9.25% | 363.1M -10.29% | 404.8M -4.29% | |
Retained Earnings | -632.5M +13.31% | -558.2M +18.37% | -471.6M +26.38% | -373.1M +41.20% | |
Total Stockholders Equity | -108.5M +138.31% | -45.5M -41.02% | -77.2M -69,019.64% | 112,000 -99.88% | |
Total Shares Outstanding | 56.7M +1.91% | 55.6M +31.48% | 42.3M +1.14% | 41.8M +1.22% | |
Cash Flow | |||||
Cash from Operating Activities | -86.1M -14.25% | -100.4M -14.99% | -118.1M -161.00% | 193.6M +485.30% | |
Capital Expenditures | 50,000 -94.48% | 906,000 -25.98% | 1.2M +1.16% | 1.2M -63.48% | |
Cash from Investing Activities | 112.0M +474.67% | -29.9M -120.70% | 144.4M +159.12% | -244.3M -775.43% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 1.0M -99.03% | 105.4M +5,829.58% | 1.8M +0.85% | 1.8M -92.14% | |
Financials Ratio | |||||
Gross Margin | N/A N/A | 22.93% N/A | N/A N/A | N/A N/A | |
Operating Margin | -279.49% -38.48% | -454.31% +43.80% | -315.93% -48.14% | -609.20% -92.02% | |
Return on Assets | -30.82% +1.38% | -30.40% +6.67% | -28.50% +21.00% | -23.55% -9.89% | |
Return on Equity | 96.45% -31.67% | 141.17% -44.72% | 255.39% +213.74% | -224.54% +169.32% | |
Revenue Growth | 36.75% +208.66% | -33.83% -143.57% | 77.63% -94.28% | 1,357.77% +556.74% | |
Current Ratio | 2.73 -26.66% | 3.73 -9.35% | 4.11 -35.43% | 6.37 -32.56% | |
Cash Ratio | 1.35 +63.54% | 0.83 -39.79% | 1.37 +45.36% | 0.95 -54.47% | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow